Health Care Reform: For Biopharmas There Is Much To Like
Executive Summary
The passage of health reform was a momentous juncture for the health care industry, but is also just the beginning of years of policy development that amend or define the crucial details of the 2010 proposals. Analysts are still tallying the reform bill's final cost to biopharma companies; even so, the industry stands to gain more it gives up with the landmark legislation's passing.
You may also be interested in...
Physicians Have Bigger Stake In Patients' Total Care Under Medicare ACOs
One year after the passage of health care reform, recommendations around some of the more far-reaching elements of the legislation are beginning to emerge. One proposal biopharmas cannot afford to ignore: Medicare sanctioned accountable care organizations.
A Look Back At 2010: In Search Of New Biopharma Models
2010 was a year of transition, filled with the exploration of new industry models. Health care reform hinted at short-term pain and long-term gain while investment, R&D and commercial challenges combined with a heightened sense of industry desperation to bring out biopharma's creative side. But as with any experiment, there is ample risk of failure.
A Look Back At 2010: In Search Of New Biopharma Models
2010 was a year of transition, filled with the exploration of new industry models. Health care reform hinted at short-term pain and long-term gain while investment, R&D and commercial challenges combined with a heightened sense of industry desperation to bring out biopharma's creative side. But as with any experiment, there is ample risk of failure.